A user discussed CagriSema in the context of clinical trial data, noting its high efficacy with an average weight loss of 22.7%. However, they highlighted that the Cagrilintide component is non-selective and can cause increased nausea and ‘conditioned taste avoidance’ compared to newer selective amylin agonists.